Blog
RSS FeedPosted by Michael Wonder on 05 Jun 2017
Amgen submits regulatory applications for Repatha (evolocumab) cardiovascular outcomes data in US and Europe
5 June 2017 - Amgen today announced the submission of a supplemental biologics license application to the U.S. FDA and a ...
Posted by Michael Wonder on 05 Jun 2017
FDA expands use of Sapien 3 artificial heart valve for high-risk patients
5 June 2017 - Expanded use approval relies on real world evidence. ...
Posted by Michael Wonder on 05 Jun 2017
Outcry over EpiPen prices hasn’t made them lower
4 June 2017 - A few weeks ago, after some particularly incompetent parenting on my part (nuts in the dessert, ...
Posted by Michael Wonder on 05 Jun 2017
Moving in the wrong direction — health care under the AHCA
31 May 2017 - On May 4, the U.S. House of Representatives resurrected Republican efforts to enact major health care legislation ...
Posted by Michael Wonder on 05 Jun 2017
The first hundred days for health care
31 May 2017 - Like my predictions about what a Republican win in the 2016 election would mean for U.S. health ...
Posted by Michael Wonder on 05 Jun 2017
The specialists’ stranglehold on medicine
3 June 2017 - Republicans are trying to cut health care spending. But hacking away at Medicaid, weakening coverage requirements ...
Posted by Michael Wonder on 05 Jun 2017
The doctor is in. Co-pay? $40,000.
3 June 2017 - When John Battelle’s teenage son broke his leg at a suburban soccer game, naturally the first ...
Posted by Michael Wonder on 05 Jun 2017
Obama unwittingly handed Trump a weapon to cripple the health law
3 June 2017 - Obama administration officials knew they were on shaky ground in spending billions of dollars on health ...
Posted by Michael Wonder on 05 Jun 2017
The single payer party? Democrats shift left on health care
3 June 2017 - For years, Republicans savaged Democrats for supporting the Affordable Care Act, branding the law — with ...
Posted by Michael Wonder on 04 Jun 2017
Measuring value and benefit—a matter of perspective
2 June 2017 - There is growing concern about the sustainability of health-care systems as the populations of high-income countries age ...
Posted by Michael Wonder on 04 Jun 2017
ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising only two medicines
1 June 2017 - Priority review voucher submitted in US with anticipated target action date of 6 months. ...
Posted by Michael Wonder on 04 Jun 2017
Merck receives accelerated approval of Keytruda (pembrolizumab), the first FDA approved anti-PD-1 therapy
4 September 2014 - Merck today announced that the US FDA has approved Keytruda (pembrolizumab) at a dose of 2 ...
Posted by Michael Wonder on 04 Jun 2017
FDA approves expanded indication for Merck’s Keytruda (pembrolizumab) for the treatment of patients with advanced melanoma
18 December 2015 - Keytruda is now the first and only anti-PD-1 therapy to achieve superior overall survival compared to ipilimumab. ...
Posted by Michael Wonder on 04 Jun 2017
FDA approves Merck’s Keytruda (pembrolizumab) for patients with recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy
5 August 2016 - Merck today announced that the U.S. FDA has approved Keytruda (pembrolizumab), the company’s anti-PD-1 (programmed death ...
Posted by Michael Wonder on 04 Jun 2017
Pfizer hikes U.S. prices of 91 drugs by average 20% in 2017
2 June 2017 - Pfizer has hiked the price of nearly a hundred drugs by an average of 20% so ...